Mirada’s products support timepoints of patient for follow-up assessment of PET or SPECT, MR and CT or any hybrid combination of the two.

The results and complex findings obtained from the trial are automatically sent to the trial-specific database in a pre-defined trial specific format which avoid errors and reduces time.

Mirada Medical chief executive Hugh Bettesworth said by combining their knowledge of the trials industry with its technologies to enable software assisted multi-modality and novel molecular image quantification over successive patient follow ups, they can offer new levels of productivity and data compliance in cancer trials.

ABX-CRO GM and founder Andreas Kluge said they feel that Mirada and ABX-CRO are natural partners in their mission to make quantitative molecular imaging a reality not only in clinical medicine but also in late-stage drug development.